CD274 and neoplasm: Pembrolizumab, MK-3475, a humanized monoclonal IgG4 anti-PD-1 antibody, is another anti-PD1 showing robust anti-tumor activity and significantly improved PFS and OS than chemotherapy as first-line therapy for metastatic NSCLC with PD-L1 tumor proportion score of at least 50%.